Top Stories
Enrollment was halted in Phase III depression studies of the KV7 channel opener, overshadowing a regulatory filing in epilepsy.
The most advanced candidate Novo acquired from Kallyope is K-554, an IND-ready, potentially first-in-class peptide.
Eli Lilly's drug duo was approved for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.
The drug was previously approved to treat the neurological manifestations of Niemann-Pick disease type C.
The Bay Area biotech is advancing SIRP-targeting therapeutics, with its lead antibody in testing for secondary haemophagocytic lymphohistiocytosis.
Conference News
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tar...
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offeringAnnounced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positi...
New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) ...
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based o...
October 9-12, 2026 | Phoenix, Arizona -- New data spans pharmacotherapy, imaging and diagnostics, and device therapy for patients with cardiomyopathyThe HFSA Annual Scientific Meeting takes place Octo...
